Sign In
Buy OPORF
$0.350
+0 (+0%)
At Close: Jun 03, 2026
hVIVO win with Decoy Therapeutics signals shift towards broader contract research market, says broker
04:41am, Tuesday, 02'nd Jun 2026
hVIVO PLC's (AIM:HVO) consultancy contract with Decoy Therapeutics, announced on Monday, is a small deal by any financial measure, but Peel Hunt's reading of it points to something more strategically
hVIVO signs consultancy deal with antiviral developer Decoy Therapeutics
11:04am, Monday, 01'st Jun 2026
hVIVO PLC (AIM:HVO), the clinical development company specialising in human challenge trials, has signed a consultancy contract with Decoy Therapeutics to support the development of a novel class of
hVIVO to host capital markets day as it pitches broader clinical development role
03:07am, Wednesday, 20'th May 2026
hVIVO PLC (AIM:HVO), the human challenge trial specialist, will hold a capital markets day on 11 June in Canary Wharf as it seeks to reposition itself as a full-service early clinical development part
hVIVO sees uptick in human challenge trial demand - ICYMI
02:50am, Saturday, 09'th May 2026
hVIVO PLC (AIM:HVO) chief executive, Yamin ‘Mo' Khan, talked with Proactive about the company's latest contract win with a new European biotech client for an influenza human challenge trial. Khan e
hVIVO shares surge as contract wins build investor confidence
03:52am, Thursday, 07'th May 2026
Shares in hVIVO PLC (AIM:HVO), the human challenge trial specialist, were up 7% to 7.99p, extending a recovery that has seen the stock gain around 25% since the start of the year, after the latest in
Human challenge trials come of age as hVIVO lands world-first whooping cough contract
11:16am, Wednesday, 22'nd Apr 2026
The signing of a pivotal phase III human challenge trial for a whooping cough vaccine marks a turning point not just for hVIVO PLC (AIM:HVO), but for the entire human challenge trial model as a credib
hVIVO full-year results: Growth strategy and outlook - ICYMI
12:45am, Saturday, 18'th Apr 2026
hVIVO PLC (AIM:HVO) chief executive, Yamin “Mo” Khan, talked with Proactive about the company's full-year results, highlighting financial performance, strategic progress and outlook for 2026. Kha
hVIVO plc (OPORF) Q4 2025 Earnings Call Transcript
10:42am, Thursday, 16'th Apr 2026
hVIVO plc (OPORF) Q4 2025 Earnings Call Transcript
Cavendish sees hVIVO's transition year setting platform for recovery as CRO market conditions stabilise
11:22am, Wednesday, 15'th Apr 2026
hVIVO PLC (AIM:HVO), the human challenge trial specialist, reported a sharp fall in revenue and profitability for 2025, but Cavendish argued on Wednesday that the numbers mask a more encouraging under
hVIVO targets strong return to growth after transition year
02:46am, Wednesday, 15'th Apr 2026
hVIVO PLC (AIM:HVO), the AIM-listed human challenge trial specialist, expects high single-digit revenue growth in 2026, weighted to the second half, as it moves past a year of deliberate restructurin
Cavendish maintains buy on hVIVO after influenza trial contract win, sees revenues weighted to 2026
10:19am, Tuesday, 14'th Apr 2026
Cavendish has maintained its 'buy' recommendation and 16.5p target price on hVIVO PLC (AIM:HVO) following the clinical development specialist's announcement of a new influenza human challenge trial co
hVIVO shares rise 11% as influenza trial win and rebrand signal integrated strategy bearing fruit
03:51am, Tuesday, 14'th Apr 2026
hVIVO PLC (AIM:HVO) shares rose 11% to 8.18p after the clinical development specialist announced a new influenza human challenge trial contract and unveiled a unified brand identity on the same day, m
hVIVO inks influenza trial contract and unveils unified brand as integrated platform strategy takes shape
02:47am, Tuesday, 14'th Apr 2026
The AIM-listed clinical development specialist completes its transformation with a new deal and a rebrand consolidating four service lines under one identity. hVIVO PLC (AIM:HVO) has signed a contrac
hVIVO surges 50% in two days as ILiAD funding boosts contract hopes
08:00am, Thursday, 12'th Feb 2026
hVIVO PLC (AIM:HVO) shares have jumped 50% in two days to 9.13p after ILiAD Biotechnologies secured $115 million in Series B financing, strengthening expectations that a previously signed letter of in
hVIVO plc (OPORF) Q4 2025 Sales/Trading Call Transcript
04:20pm, Saturday, 31'st Jan 2026
hVIVO plc (OPORF) Q4 2025 Sales/Trading Call Transcript
